lunes, 18 de marzo de 2019

Stroke Shoe Retrains the Brain - Ivanhoe Broadcast News, Inc.

Stroke Shoe Retrains the Brain - Ivanhoe Broadcast News, Inc.





Marketing


In the United States every year close to 800,000 people suffer a stroke, but a new kind of shoe is helping stroke victims get back on the right foot. See how a simple, take-home device is making a difference




From the joyful anticipation to fear that the child you longed for was in danger. See how doctors used a unique procedure to save a couple’s unborn baby..




About one in 50 people suffer from OCD, a disease that turns intrusive thoughts into compulsive behaviors. Anti-depressants help with OCD but investigators in Texas are trying new medications targeting different brain messengers.




Neuroblastoma claims the lives of more children under the age of five than any other cancer. But one little fighter is a four-year-old survivor of neuroblastoma, and is donating his own blood cells to science




It’s a disease that can be described as someone having ALS, Alzheimer’s and schizophrenia all at the same time. Meet a researcher who has found the key to not only preventing Huntington’s disease, but possibly reversing its symptoms






Doctor's In-depth Interview of the week
 
Cooling Cap Helps More Cancer Patients Save Their Hair 
David Riseberg, MD, Medical Oncologist
Mercy Medical Center



Quote of the week:

Six mistakes mankind keeps making century after century: Believing that personal gain is made by crushing others; Worrying about things that cannot be changed or corrected; Insisting that a thing is impossible because we cannot accomplish it; Refusing to set aside trivial preferences; Neglecting development and refinement of the mind; Attempting to compel others to believe and live as we do.” 

— Marcus Tullius Cicero








If you know of an innovative medical treatment, send us the name of the treatment,  name of the doctor and city. We may be able to cover it in one of our series: newsalert@ivanhoe.com

Website Informationwebdoctor@ivanhoe.com

Content Licensing: jcherry@ivanhoe.com

No hay comentarios:

Publicar un comentario